Navigation Links
New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
Date:1/13/2009

-Growing Body of Data Supports XELOX as Effective Alternative to Standard of Care-

NUTLEY, N.J., Jan. 13 /PRNewswire-FirstCall/ -- Overall survival results from a 14-month follow-up of the international, Phase III NO16966 study confirm that oral Xeloda(R) plus oxaliplatin (XELOX) is comparable to a current standard treatment, FOLFOX-4 (infused 5-FU/leucovorin plus oxaliplatin) in the first-line treatment of advanced (metastatic) colorectal cancer.

In the study, patients receiving XELOX lived for a median of 19.0 months, while patients receiving FOLFOX-4 lived for a median of 18.5 months. The consistency of these results were also further demonstrated in a subset population from the original two-arm part of the study (XELOX v. FOLFOX). These data will be presented later this week at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, Calif.

"These compelling data validate previous studies showing that XELOX is comparable to FOLFOX-4 for the treatment of advanced colorectal cancer, while providing the added flexibility of the proven oral component Xeloda," said Edward Chu, M.D., chief of medical oncology, Yale Cancer Center. "Together, these studies confirm the value and importance of combination therapy with oral Xeloda for the thousands of patients with this insidious disease."

Colorectal cancer is the third most common cancer in the United States. The American Cancer Society estimated that in 2008 more than 148,000 people in the U.S. would be diagnosed and about 50,000 people would die from the disease. (1)

Previous data reported from the NO16966 study showed that XELOX is comparable to FOLFOX-4 in terms of progression-free survival, and the addition of Avastin to chemotherapy (FOLFOX-4 and XELOX) significantly improved progression-free survival by investigator assessment compared to chemotherapy alone. Fu
'/>"/>

SOURCE Roche
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
2. Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
3. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
4. DaVita Strives to Improve Quality of Life and Reduce Overall Costs of Kidney Care Through Community-Based Education
5. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
6. Karmanos Cancer Institute Researchers Show Phase I Immunotherapy with Armed T Cells Improve Overall Survival of Metastatic Breast Cancer Patients
7. New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
8. Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer
9. New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C)
10. TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
11. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... LOVELAND, Colo. , May 24, 2013  Heska Corporation ... veterinary diagnostic and specialty products, announced today that Dr. ... executive officer, and Jason Napolitano , executive ... Second Annual Marcum MicroCap Conference, which is being held May ... at the Grand Hyatt Hotel. The Company,s ...
(Date:5/24/2013)... 24, 2013 The potential of ... delivery of therapeutic agents has been receiving undeniable attention ... showing significant promise. The crucial formulation considerations for orally ... play a major role in the efficiency of pulmonary ... development of new formulation techniques and devices in recent ...
(Date:5/23/2013)... 2013 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... President and Chief Executive Officer of Neurocrine Biosciences, will be ... Health Care Conference in Boston.   The live ... Eastern Time / 8:20 a.m. Pacific Time.  The presentation will ... at http://www.neurocrine.com . If you are ...
Breaking Medicine Technology:Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2
... is pleased to announce that Dr. Andrea Zobel has ... CTD Operations.  In this capacity she will assume responsibility ... operated Clinical Trial Depots once they are ... relationship with their affiliate depot network. (Logo:  ...
... 2012 What:   Life Technologies Unveils ... (CES) in Las Vegas.  The Ion Proton™ Sequencer is designed ... When:   Tuesday, January 10th thru Friday, ... Where:   Las Vegas Convention Center, North Hall, Booth #3438 ...
Cached Medicine Technology:Marken Strengthens Clinical Trial Distribution Capabilities 2
(Date:5/25/2013)... May 25, 2013 A disorder of ... of peripheral neuropathy. According to neuropathy expert doctor Helen ... is estimated that the disorder affects almost 50% of ... arising from Diabetes. The high blood sugar levels in ... patients suffering from it usually tend to have abnormally ...
(Date:5/25/2013)... May 25, 2013 Radius Engineering ... shelter company in the US and has been ... for over 35 years. M.E. and President, Walton ... of NBC Weapon Fundamentals and Shelter Engineering Standards, ... bible on shelter engineering. McCarthy is considered the ...
(Date:5/25/2013)... May 25, 2013 Pradaxa lawsuits ... life-threatening episodes of internal bleeding while using the blood thinner ... District Court, Southern District of Illinois, Bernstein Liebhard LLP reports. ... Pradaxa side effect claims had been filed in ... from 705 claims reported by the Court on May 15th. ...
(Date:5/25/2013)... Many orthodontists have thought about moving ... that cloud is. Most people would naturally assume ... provide their cloud service and support would own and ... they're selling, they'd be wrong. Cloud providers lease ... redundant facility that houses servers and related equipment to ...
(Date:5/25/2013)... CA (PRWEB) May 25, 2013 IBISWorld estimates ... grow at an average annual rate of 28.7% to $1.0 ... 17.9% in 2013. From 2002 and 2008, no new cell ... Culbert, causing relatively modest growth during that period. In the ... approved six new products. This factor contributed to the industry's ...
Breaking Medicine News(10 mins):Health News:Diabetic Neuropathy treatment hits new grounds- Neuracel launches the complete natural treatment 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 3Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3Health News:Cirrus Ortho Launches Cloud Computing for Orthodontic Industry That is Unlike Any Other 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 3
... , Cancer Treatment Centers ... from Italy , PHILADELPHIA, Nov. 18 A radiation ... to the current average of six weeks, has arrived at ... CTCA will become the first in the country to offer this ...
... , , NEW YORK, Nov. ... kids, featuring reviews and commentary about products, discoveries on the ... kids behind WAT,s-THE-WORD?! are four young boys who helped their ... Cameron, age 10, recommended to his mom a "cooler" and ...
... , AUSTIN, Texas, Nov. 18 The Advisory Board of ... launch of a new online community for athletes overcoming accident, ... forum where athletes can share stories, set goals and report ... by providing encouragement, advice and mentoring. , IWillAgain.com is inspired ...
... , CALGARY, Nov. 18 /PRNewswire-FirstCall/ - Oncolytics ... announced today that it has entered into an underwriting agreement ... common share and 0.4 of a common share purchase warrant, ... proceeds of US$12,750,000. Each whole common share purchase warrant entitles ...
... , , WASHINGTON, Nov. 18 ... a wholly owned subsidiary of ULLICO Inc., a privately ... Prescription Solutions will provide pharmacy benefit management services to ... union trust funds, union employers and their members with ...
... 300 million patients use non-steroidal anti-inflammatory drugs (NSAIDs) in ... diseases. Nearly 30% of the users suffer from gastric ... the stomach, misoprostol, a non-selective prostaglandin E1 (PGE1) analogue, ... of NSAID-induced injuries, but often induces severe adverse effects. ...
Cached Medicine News:Health News:Radiation Breakthrough Gives Breast Cancer Patients Hope in Single Dose 2Health News:Radiation Breakthrough Gives Breast Cancer Patients Hope in Single Dose 3Health News:WAT-AAH!, The First Functional Bottled Water For Kids, Announces The Release of WAT's-THE-WORD?! 2Health News:IWillAgain.com Launches Online Community for Athletes Overcoming Accident, Illness or Injury 2Health News:Oncolytics Biotech(R) Inc. Announces Terms of Unit Offering 2Health News:Oncolytics Biotech(R) Inc. Announces Terms of Unit Offering 3Health News:Oncolytics Biotech(R) Inc. Announces Terms of Unit Offering 4Health News:Union Labor Life Selects Prescription Solutions To Provide Pharmacy Benefit Management Services 2Health News:Union Labor Life Selects Prescription Solutions To Provide Pharmacy Benefit Management Services 3
... Leptin is a proteohormone with a molecular weight ... by the ob gene and produced by adipocytes [1,2]. ... in the regulation of body weight [1-3]. In ... in both men and women [4]. A relationship ...
ACTIVATED CLOTTING TIME SYSTEM...
... CT is a completely automated, ... performing clotting assays in random ... method of sample management offers ... of STAT samples without the ...
... ACTH (adrenocorticotropic hormone) is synthesized in the ... and is secreted into the peripheral circulation, ... 20 minutes [1]. ACTH is secreted in ... hypothalamus [1]. The actions of CRF are ...
Medicine Products: